Background: Non-alcoholic steatohepatitis (NASH) has become one of the most common liver diseases and is still without approved pharmacotherapy. Lifestyle interventions using exercise and diet change remain the current treatment of choice and even a small weight loss (5–7%) can already have a beneficial effect on NASH. However, the underlying molecular mechanisms of exercise and diet interventions remain largely elusive, and it is unclear whether they exert their health effects via similar or different pathways. Methods: Ldlr−/−.Leiden mice received a high fat diet (HFD) for 30 weeks to establish a severe state of NASH/fibrosis with simultaneous atherosclerosis development. Groups of mice were then either left untreated (control group) or w...
<p>Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most c...
<p>Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most c...
Non-alcoholic fatty liver disease (NAFLD) leads to steatohepatitis (NASH), fibrosis, and hepatocellu...
Non-alcoholic fatty liver disease (NAFLD) leads to steatohepatitis (NASH), fibrosis, and hepatocellu...
Background & AimsPharmacologic treatments for nonalcoholic steatohepatitis (NASH) are limited. Lifes...
International audienceThe globally prevalent disease, non-alcoholic steatohepatitis (NASH), is chara...
International audienceThe globally prevalent disease, non-alcoholic steatohepatitis (NASH), is chara...
Non-alcoholic steatohepatitis has emerged as one of the most common causes of chronic liver disease ...
International audienceThe globally prevalent disease, non-alcoholic steatohepatitis (NASH), is chara...
International audienceThe globally prevalent disease, non-alcoholic steatohepatitis (NASH), is chara...
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most common liver ...
BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most common liver ...
Contains fulltext : 152214.pdf (publisher's version ) (Open Access)BACKGROUND: Non...
Non-alcoholic fatty liver disease (NAFLD) leads to steatohepatitis (NASH), fibrosis, and hepatocellu...
Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most comm...
<p>Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most c...
<p>Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most c...
Non-alcoholic fatty liver disease (NAFLD) leads to steatohepatitis (NASH), fibrosis, and hepatocellu...
Non-alcoholic fatty liver disease (NAFLD) leads to steatohepatitis (NASH), fibrosis, and hepatocellu...
Background & AimsPharmacologic treatments for nonalcoholic steatohepatitis (NASH) are limited. Lifes...
International audienceThe globally prevalent disease, non-alcoholic steatohepatitis (NASH), is chara...
International audienceThe globally prevalent disease, non-alcoholic steatohepatitis (NASH), is chara...
Non-alcoholic steatohepatitis has emerged as one of the most common causes of chronic liver disease ...
International audienceThe globally prevalent disease, non-alcoholic steatohepatitis (NASH), is chara...
International audienceThe globally prevalent disease, non-alcoholic steatohepatitis (NASH), is chara...
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most common liver ...
BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most common liver ...
Contains fulltext : 152214.pdf (publisher's version ) (Open Access)BACKGROUND: Non...
Non-alcoholic fatty liver disease (NAFLD) leads to steatohepatitis (NASH), fibrosis, and hepatocellu...
Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most comm...
<p>Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most c...
<p>Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly turning into the most c...
Non-alcoholic fatty liver disease (NAFLD) leads to steatohepatitis (NASH), fibrosis, and hepatocellu...